Eli Lilly drug may help prevent infections at nursing homes
American pharmaceutical firm Eli Lilly and Company released new data showing that a laboratory-made protein delivered by infusion may help prevent COVID-19 infections at nursing homes.
A phase 3 trial found that nursing home residents who got the monoclonal antibody drug were 80% less likely to develop symptomatic COVID-19 compared to nursing home residents who got a placebo infusion.
Among all the study participants (including residents and staff), those who got the drug were 57% less likely to develop symptomatic COVID-19.
The Eli Lilly drug, called bamlanivimab, has FDA emergency authorization to treat people already sick with COVID-19 who might need to be hospitalized. The company says it will work with regulators to potentially expand this authorization to include nursing home residents and staff to help prevent outbreaks.
The U.S. Centers for Disease Control and Prevention advises that those who’ve had monoclonal antibody treatment wait 90 days until getting a COVID-19 vaccine.
ABC News’ Sony Salzman and Dr. Mishal Reja contributed to this report.